Rothschild Redburn upgrades Abbott Laboratories stock to Buy

Published on 10/05/2026 at 12:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Redburn raised its target from USD 119.00 to USD 127.00 on October 2, 2026. Abbott Laboratories stock costs EUR 86.91 versus EUR 86.53.

NYSE-Börsensaal Healthcare-Charts Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 NYSE-Börsensaal Editorial mit Healthcare-Aktiencharts Händlern und digitalen Kurstafeln Bildschirmen, Illustration mit AI erstellt.

Abbott Laboratories stock was trading at EUR 86.91 at Lang & Schwarz on October 5, 2026 at 12:00 p.m. CEST, up 0.44 percent versus the prior close of EUR 86.53. According to MarketBeat on October 2, 2026, Rothschild & Co Redburn upgraded the company from Neutral to Buy and raised its price target from USD 119.00 to USD 127.00.

Redburn lifts target to USD 127.00

The target increase equals 6.72 percent, calculated from USD 119.00 to USD 127.00. The upgrade puts medical-device execution at the center of the analyst view, while Abbott's latest results give the call a recent operating reference.

Abbott also launched SimpleScreen CRC in the United States on September 30, 2026. The FDA-approved blood test is intended for average-risk adults age 45 and older, and eligible Medicare Part B patients have no out-of-pocket cost, according to Abbott.

Quarterly numbers beat consensus

For the second quarter of 2026, revenue reached USD 12.59 billion, an increase of 13.00 percent from the same period a year earlier. Adjusted earnings per share came to USD 1.31 versus a consensus estimate of USD 1.28, according to MarketBeat.

That 13.00 percent revenue growth and the adjusted earnings-per-share comparison provide a stronger operating backdrop than the share price alone suggests. Abbott's third-quarter 2026 earnings are scheduled for October 21, 2026, before the market opens, according to MarketBeat.

Lang & Schwarz quote at EUR 86.91

Abbott's primary listing is on the NYSE under ticker ABT. The finance quote places market capitalization at USD 168.7 billion as of October 2, 2026, while the Lang & Schwarz reference price was EUR 86.91 on October 5, 2026 at 12:00 p.m. CEST, up 0.44 percent against the EUR 86.53 prior close dated October 2, 2026. The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.